Navigation Links
Karolinska Development to Divest Portfolio Company
Date:6/29/2010

STOCKHOLM, June 29, 2010 /PRNewswire/ -- Today, Karolinska Development has divested Cogmed, one of Karolinska Development's portfolio companies, to Pearson where it will become part of Pearson's Clinical Assessment business. Karolinska Development and other owners will receive an up front payment, as well as tiered royalties up to double digit levels until June 2012 on Cogmed sales. Karolinska Development holds 51.83 percent of Cogmed. Pearson will take possession on June 29, 2010.

The financial details of the acquisition have not been disclosed.

Redwood Capital Group acted as exclusive financial advisor to Cogmed in connection with the transaction.

TO THE EDITORS

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

About Cogmed

Cogmed was founded in 2001. The company provides scientifically developed and clinically validated software based working memory training products for people with attention deficits. Further, Cogmed supports Swedish and international research within working memory training.http://www.cogmed.com

About Pearson Clinical Assessment

http://www.pearsonassessments.com

About Redwood Capital

Redwood Capital Group is an investment banking firm serving the technology, communications and media & business services industries. The firm focuses on mergers & acquisitions, debt and equity financings, and financial advisory services for its clients worldwide. http://www.redcapgroup.com

    For further information, please contact:

    Conny Bogentoft, CEO Karolinska Development
    Tel: +46(0)706-88-61-43,
    e-mail: conny.bogentoft@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy
2. Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
3. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
4. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
5. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. Marcadia and Lilly Sign Development, License Agreement for Novel Glucagon Program in Severe Hypoglycemia
8. Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline
9. Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering
10. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
11. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):